Literature DB >> 9119446

Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.

H Zhang1, Z Zhong, L A Pirofski.   

Abstract

Cryptococcus neoformans causes meningitis in 6 to 8% of individuals with AIDS. Recently, immunotherapeutic modalities including antibody therapy have been proposed for the treatment of cryptococcal meningitis in AIDS patients. This is a rational approach because existing antifungal agents fail to eradicate the infection in the setting of profound immunosuppression. Both murine and human antibodies elicited by the investigational cryptococcal capsular polysaccharide vaccine glucuronoxylomannan-tetanus toxoid (GXM-TT) have been shown to be biologically functional in different model systems. The human immunoglobulin M (lambda) GXM monoclonal antibody (MAb) 2E9 expresses idiotypes that are also found in naturally occurring anti-GXM antibodies and opsonic GXM-TT sera. However, the specificity of human anti-GXM antibodies and their possible role in protection against cryptococcosis are not known. In an effort to discover epitopes that are recognized by human anti-GXM antibodies, we screened a random decapeptide phage display library with the human anti-GXM MAb 2E9. An enzyme-linked immunosorbent assay (ELISA)-based screening method led to the selection of phages with peptide inserts that bound 2E9 and inhibited 2E9-GXM binding. Analysis of the amino acid sequences of these phages revealed an increased frequency of combinations of QTGLD residues. Inhibition ELISAs demonstrated that phages with QTG/TL/D motifs inhibited 2E9-GXM binding better than phages with different motifs. A peptide synthesized from one of the inhibitory phages, peptide 13 (GMDGT QLDRW), inhibited GXM binding to solid-phase 2E9 and 2E9 binding to solid-phase GXM. Peptide 13 also inhibited the GXM binding of GXM-TT immune sera and naturally occurring serum antibodies from human immunodeficiency virus (HIV)-negative, but not HIV-positive, individuals. Taken together, our data indicate that the peptide epitopes selected by 2E9 mimic GXM epitopes and that peptide 13 may be a mimotope of a GXM epitope that is recognized by human anti-GXM antibodies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9119446      PMCID: PMC175112          DOI: 10.1128/iai.65.4.1158-1164.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Sequences of variable regions of hybridoma antibodies to alpha (1----6) dextran in BALB/c and C57BL/6 mice.

Authors:  S K Sikder; P N Akolkar; P M Kaladas; S L Morrison; E A Kabat
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

2.  Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3.

Authors:  R Hoess; U Brinkmann; T Handel; I Pastan
Journal:  Gene       Date:  1993-06-15       Impact factor: 3.688

3.  A comprehensive set of sequence analysis programs for the VAX.

Authors:  J Devereux; P Haeberli; O Smithies
Journal:  Nucleic Acids Res       Date:  1984-01-11       Impact factor: 16.971

4.  Variable region sequences and idiotypic expression of a protective human immunoglobulin M antibody to capsular polysaccharides of Neisseria meningitidis group B and Escherichia coli K1.

Authors:  F H Azmi; A H Lucas; H V Raff; D M Granoff
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

5.  Characterization of naturally occurring autoantibodies against tumour necrosis factor-alpha (TNF-alpha): in vitro function and precise epitope mapping by phage epitope library.

Authors:  M Sioud; A Dybwad; L Jespersen; S Suleyman; J B Natvig; O Førre
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

6.  Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection.

Authors:  J Mukherjee; L A Pirofski; M D Scharff; A Casadevall
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

7.  Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages.

Authors:  S Mukherjee; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

8.  Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan.

Authors:  A Casadevall; M DeShaw; M Fan; F Dromer; T R Kozel; L A Pirofski
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

9.  Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals.

Authors:  M Deshaw; L A Pirofski
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

10.  Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan.

Authors:  D C Houpt; G S Pfrommer; B J Young; T A Larson; T R Kozel
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441

View more
  13 in total

1.  Antibody response to Cryptococcus neoformans proteins in rodents and humans.

Authors:  L C Chen; D L Goldman; T L Doering; L a Pirofski; A Casadevall
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice.

Authors:  Ulrike K Buchwald; Andrew Lees; Michael Steinitz; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 3.  Phage-displayed peptide libraries.

Authors:  M B Zwick; J Shen; J K Scott
Journal:  Curr Opin Biotechnol       Date:  1998-08       Impact factor: 9.740

4.  Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies.

Authors:  A Nakouzi; P Valadon; J Nosanchuk; N Green; A Casadevall
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

5.  Antifungal activity of a human antiglucuronoxylomannan antibody.

Authors:  Z Zhong; L A Pirofski
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

6.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Structural and functional properties of the Trichosporon asahii glucuronoxylomannan.

Authors:  Fernanda L Fonseca; Susana Frases; Arturo Casadevall; Olga Fischman-Gompertz; Leonardo Nimrichter; Marcio L Rodrigues
Journal:  Fungal Genet Biol       Date:  2009-03-12       Impact factor: 3.495

8.  Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.

Authors:  Robert W Maitta; Kausik Datta; Qing Chang; Robin X Luo; Bradley Witover; Krishanthi Subramaniam; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

9.  Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan.

Authors:  Kausik Datta; Andrew Lees; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2008-06-04

Review 10.  A Call to Arms: Quest for a Cryptococcal Vaccine.

Authors:  Marley C Caballero Van Dyke; Floyd L Wormley
Journal:  Trends Microbiol       Date:  2017-11-02       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.